Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Medroxyprogesterone acetate compositions|
|Abstract:||A pharmaceutical vehicle for parenteral administration of medroxyprogesterone acetate is disclosed comprising an aqueous solution of sodium sulfate, quaternary ammonium wetting agent, and a member selected from glycerin, propylene glycol, polyethylene glycol, and polypropylene glycol. The compositions may contain a non-ionic hydrophilic colloid as a preferred adjuvant. Compositions are useful for suspending large amounts, e.g., from 200 to 600 mg./ml. of medroxyprogesterone acetate and maintaining suitable suspendability and syringeability characteristics and are used for the known therapeutic indications for medroxyprogesterone acetate.|
|Inventor(s):||Lamb; Donald J. (Portage, MI)|
|Assignee:||The Upjohn Company (Kalamazoo, MI)|
1. An aqueous suspension for parenteral administration comprising from about 200 to about 600 mg./ml. of suspended medroxyprogesterone acetate; water; from about 0.8% w/v to about
1.5% w/v of sodium sulfate; from about 0.1% w/v to about 1.4% w/v of a parenterally acceptable quaternary ammonium wetting agent; and from about 2% w/v to about 5% w/v of a member selected from the group consisting of glycerin, propylene glycol,
polyethylene glycol and polypropylene glycol.
2. The composition of claim 1 additionally containing a parenterally acceptable non-ionic hydrophilic colloid in a concentration not exceeding 1.5% w/v.
3. The composition of claim 1 wherein the suspended medroxyprogesterone acetate is a fineness of 99% less than 10 microns and 75% less than 5 microns.
4. The composition of claim 3 additionally containing a parenterally acceptable non-ionic hydrophilic colloid in a concentration not exceeding 1.5% w/v.